Literature DB >> 40610

Optimal conditions for the assay of fibroblast neuraminidase with different natural substrates.

L Caimi, A Lombardo, A Preti, U Wiesmann, G Tettamanti.   

Abstract

A method for the assay of neuraminidase in human cultured fibroblasts has been worked out. The substrates, all naturally occurring, were: sialyloligosaccharides (alpha(2 lead to 3)sialyllactose, alpha(2 leads to 6)sialyllactose, disialyllactose), sialylglycoplipids (disialogangliosides GD1a and GD1b), sialylglycoproteins and sialylglycopeptides (ovine submaxillary glycoprotein and its pronase-glycopeptides). The method was based on the determination of the enzymically liberated N-acetylneuraminic acid (NeuAc) by a chromatographic-colorimetric microprocedure. The enzyme acted on sialyloligosaccharides and, in the presence of Triton X-100, on gangliosides, while it did not appreciably affect sialylglycoproteins and sialylglycopeptides. The optimum pH was 4.0 for all tested substrates; the Km values were higher for sialyloligosaccharides (about 10(-3) M), lower for gangliosides (about 10(-4) M); the apparent maximum velocity was higher with alpha(2 leads to 3)sialyllactose (400 mU/mg protein); the reaction rate was linear with time for up to 2 h, and with up to 0.6 mg of enzymic protein. The assay method proved to be sufficiently sensitive (3-4 nmol liberated NeuAc), simple, and reproducible (mean activity on pooled fibroblasts with alpha(2 leads to 3)sialyllactose: 400 mU +/- 6 S.E.).

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 40610     DOI: 10.1016/0005-2744(79)90234-1

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  9 in total

1.  Kinetics of Vibrio cholerae sialidase action on gangliosidic substrates at different supramolecular-organizational levels.

Authors:  B Venerando; B Cestaro; A Fiorilli; R Ghidoni; A Preti; G Tettamanti
Journal:  Biochem J       Date:  1982-06-01       Impact factor: 3.857

2.  Cellular localization of neuraminidases in cultured human fibroblasts.

Authors:  M Zeigler; G Bach
Journal:  Biochem J       Date:  1981-09-15       Impact factor: 3.857

3.  Different behavior of ghost-linked acidic and neutral sialidases during human erythrocyte ageing.

Authors:  C Tringali; A Fiorilli; B Venerando; G Tettamanti
Journal:  Glycoconj J       Date:  2001-05       Impact factor: 2.916

4.  Modification of sialidase levels and sialoglycoconjugate pattern during erythroid and erytroleukemic cell differentiation.

Authors:  Cristina Tringali; Luigi Anastasia; Nadia Papini; Anna Bianchi; Luisa Ronzoni; Maria Domenica Cappellini; Eugenio Monti; Guido Tettamanti; Bruno Venerando
Journal:  Glycoconj J       Date:  2007-01       Impact factor: 2.916

5.  Mucolipidosis IV, a sialolipidosis due to ganglioside sialidase deficiency.

Authors:  L Caimi; G Tettamanti; B Berra; F Omodeo Sale; C Borrone; R Gatti; P Durand; J J Martin
Journal:  J Inherit Metab Dis       Date:  1982       Impact factor: 4.982

6.  Combined deficiency of beta-galactosidase and neuraminidase: three affected siblings in a French family.

Authors:  I Maire; A R Nivelon-Chevallier
Journal:  J Inherit Metab Dis       Date:  1981       Impact factor: 4.982

7.  Ganglioside GM3 sialidase activity in fibroblasts of normal individuals and of patients with sialidosis and mucolipidosis IV. Subcellular distribution and and some properties.

Authors:  M Lieser; E Harms; H Kern; G Bach; M Cantz
Journal:  Biochem J       Date:  1989-05-15       Impact factor: 3.857

8.  Cherry-red spot myoclonus syndrome and alpha-neuraminidase deficiency: neurophysiological, pharmacological and biochemical study in an adult.

Authors:  S Franceschetti; G Uziel; S Di Donato; L Caimi; G Avanzini
Journal:  J Neurol Neurosurg Psychiatry       Date:  1980-10       Impact factor: 10.154

9.  Characterization of human placental neuraminidases. Stability, substrate specificity and molecular weight.

Authors:  D McNamara; G Beauregard; H V Nguyen; D L Yan; M Bélisle; M Potier
Journal:  Biochem J       Date:  1982-08-01       Impact factor: 3.857

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.